Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 1;41(1):1-19.
doi: 10.1097/IAE.0000000000003003.

THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A Review

Jeffrey S Heier  1 , Rishi P Singh  2 , Charles C Wykoff  3 , Karl G Csaky  4 , Timothy Y Y Lai  5 , Anat Loewenstein  6 , Patricio G Schlottmann  7 , Liliana P Paris  8 , Peter D Westenskow  8 , Carlos Quezada-Ruiz  9   10
Affiliations
Review

THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A Review

Jeffrey S Heier et al. Retina. .

Abstract

Purpose: To provide a concise overview for ophthalmologists and practicing retina specialists of available clinical evidence of manipulating the angiopoietin/tyrosine kinase with immunoglobulin-like and endothelial growth factor-like domains (Tie) pathway and its potential as a therapeutic target in retinal vascular diseases.

Methods: A literature search for articles on the angiopoietin/Tie pathway and molecules targeting this pathway that have reached Phase 2 or 3 trials was undertaken on PubMed, Association for Research in Vision and Ophthalmology meeting abstracts (2014-2019), and ClinicalTrials.gov databases. Additional information on identified pipeline drugs was obtained from publicly available information on company websites.

Results: The PubMed and Association for Research in Vision and Ophthalmology meeting abstract search yielded 462 results, of which 251 publications not relevant to the scope of the review were excluded. Of the 141 trials related to the angiopoietin/Tie pathway on ClinicalTrials.gov, seven trials focusing on diseases covered in this review were selected. Vision/anatomic outcomes from key clinical trials on molecules targeting the angiopoietin/Tie pathway in patients with retinal vascular diseases are discussed.

Conclusion: Initial clinical evidence suggests a potential benefit of targeting the angiopoietin/Tie pathway and vascular endothelial growth factor-A over anti-vascular endothelial growth factor-A monotherapy alone, in part due to of the synergistic nature of the pathways.

PubMed Disclaimer

Comment in

  • Correspondence.
    Achiron RN, Achiron A, Tuuminen R. Achiron RN, et al. Retina. 2021 Sep 1;41(9):e55-e56. doi: 10.1097/IAE.0000000000003184. Retina. 2021. PMID: 33840787 No abstract available.
  • Reply.
    Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, Schlottmann PG, Paris LP, Westenskow PD, Quezada-Ruiz C. Heier JS, et al. Retina. 2021 Sep 1;41(9):e56-e58. doi: 10.1097/IAE.0000000000003183. Retina. 2021. PMID: 34432748 No abstract available.

References

    1. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health 2017;5:e1221–e1234.
    1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313–319.e311.
    1. Miller JW. Age-related macular degeneration revisited—piecing the puzzle: the LXIX Edward Jackson Memorial Lecture. Am J Ophthalmol 2013;155:1–35.e13.
    1. Boyer DS, Hopkins JJ, Sorof J, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4:151–169.
    1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124–136.

LinkOut - more resources